D. E. Shaw & Co., Inc. Caribou Biosciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$5.1 - $9.74 $1.02 Million - $1.95 Million	-200,143 Reduced 87.77%	27,884 $151,000
Q1 2022 May 16, 2022	BUY	$8.42 - $15.32 $729,727 - $1.33 Million	86,666 Added 61.31%	228,027 $2.09 Million
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $2.06 Million - $3.29 Million	141,361 New	141,361 $2.13 Million

137

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $93.7M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.